10 Best Micro Cap 50m for November 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market environment is characterized by heightened volatility and a renewed focus on fundamentals, with investors seeking resilient, undervalued opportunities across sectors. Our selection methodology leverages ValueSense’s proprietary intrinsic value models, quality ratings, and deep-dive financial analysis tools[1][2]. Stocks are screened for attractive valuations, solid quality metrics, and sectoral diversification, ensuring a balanced watchlist that spans technology, healthcare, consumer, and industrials. Each pick is evaluated for growth potential, risk profile, and alignment with value investing principles.
Featured Stock Analysis
Veritone, Inc. (VERI)
| Metric | Value |
|---|---|
| Market Cap | $310.7M |
| Quality Rating | 4.5 |
| Intrinsic Value | $23.7 |
| 1Y Return | 92.6% |
| Revenue | $90.9M |
| Free Cash Flow | ($27.2M) |
| Revenue Growth | (31.1%) |
| FCF margin | (29.9%) |
| Gross margin | 60.8% |
| ROIC | (67.8%) |
| Total Debt to Equity | 8,060.6% |
Investment Thesis
Veritone, Inc. is an AI-driven software company specializing in enterprise solutions for media, legal, and government sectors. With a market cap of $310.7M and a strong gross margin of 60.8%, Veritone stands out for its advanced AI platform and recurring revenue streams. Despite a challenging revenue growth rate of 31.1% and negative free cash flow, the company’s intrinsic value is estimated at $23.7, suggesting significant upside relative to its current valuation. The 1-year return of 92.6% highlights recent momentum, possibly driven by AI adoption trends and strategic partnerships.
Key Catalysts
- Expansion of AI solutions into new verticals
- Strategic partnerships and enterprise contracts
- Potential for margin improvement as scale increases
Risk Factors
- High leverage (Total Debt to Equity: 8,060.6%)
- Negative free cash flow and declining revenue
- Execution risk in scaling AI offerings
Ironwood Pharmaceuticals, Inc. (IRWD)
| Metric | Value |
|---|---|
| Market Cap | $310.5M |
| Quality Rating | 5.6 |
| Intrinsic Value | $10.3 |
| 1Y Return | -51.4% |
| Revenue | $308.5M |
| Free Cash Flow | $29.9M |
| Revenue Growth | (23.0%) |
| FCF margin | 9.7% |
| Gross margin | 99.7% |
| ROIC | 88.8% |
| Total Debt to Equity | (195.3%) |
Investment Thesis
Ironwood Pharmaceuticals operates in the biopharmaceutical sector, focusing on gastrointestinal therapies. With a market cap of $310.5M and a robust gross margin of 99.7%, the company demonstrates operational efficiency. The intrinsic value is $10.3, and the quality rating is 5.6, indicating a solid fundamental profile. However, the stock has experienced a significant 1-year decline of -51.4%, reflecting sector headwinds and possibly pipeline setbacks. Positive free cash flow $29.9M and a strong ROIC of 88.8% support the company’s ability to generate returns on invested capital.
Key Catalysts
- New product launches or regulatory approvals
- Expansion into additional therapeutic areas
- Cost optimization initiatives
Risk Factors
- High negative debt to equity ratio (195.3%)
- Revenue contraction 23.0%
- Market volatility in biotech sector
Jack in the Box Inc. (JACK)
| Metric | Value |
|---|---|
| Market Cap | $305.7M |
| Quality Rating | 4.4 |
| Intrinsic Value | $1,641.2 |
| 1Y Return | -67.1% |
| Revenue | $1,488.4M |
| Free Cash Flow | $49.4M |
| Revenue Growth | (6.7%) |
| FCF margin | 3.3% |
| Gross margin | 28.7% |
| ROIC | 1.0% |
| Total Debt to Equity | (329.0%) |
Investment Thesis
Jack in the Box is a well-known quick-service restaurant chain with a market cap of $305.7M. Despite a challenging year (-67.1% 1Y return), the company’s intrinsic value is calculated at $1,641.2, suggesting deep undervaluation. Revenue stands at $1,488.4M, with a modest free cash flow of $49.4M. The quality rating of 4.4 and a gross margin of 28.7% reflect operational stability, while the company’s ability to generate cash flow even in a tough environment is notable.
Key Catalysts
- Menu innovation and digital ordering growth
- Franchise expansion and cost controls
- Recovery in consumer spending
Risk Factors
- High leverage (Total Debt to Equity: 329.0%)
- Slow revenue growth 6.7%
- Competitive pressures in fast food sector
Montana Technologies Corporation (AIRJ)
| Metric | Value |
|---|---|
| Market Cap | $305.7M |
| Quality Rating | 5.3 |
| Intrinsic Value | $3.7 |
| 1Y Return | -5.8% |
| Revenue | $0.0 |
| Free Cash Flow | ($6,096.8K) |
| Revenue Growth | N/A |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | (1,665.9%) |
| Total Debt to Equity | 0.0% |
Investment Thesis
Montana Technologies is an early-stage company in the industrial technology space, with a market cap of $305.7M. The company currently reports no revenue, reflecting its pre-commercialization status, but holds a quality rating of 5.3 and an intrinsic value of $3.7. The negative free cash flow and extremely high negative ROIC (1,665.9%) highlight the risks typical of development-stage firms. However, the clean balance sheet (Total Debt to Equity: 0.0%) provides financial flexibility.
Key Catalysts
- Commercialization of core technology
- Strategic partnerships or licensing deals
- Progress toward revenue generation
Risk Factors
- No current revenue or gross margin
- High cash burn and negative free cash flow
- Execution risk in scaling operations
Xperi Holding Corporation (XPER)
| Metric | Value |
|---|---|
| Market Cap | $304.5M |
| Quality Rating | 6.1 |
| Intrinsic Value | $56.3 |
| 1Y Return | -26.4% |
| Revenue | $501.6M |
| Free Cash Flow | $257.0M |
| Revenue Growth | (0.9%) |
| FCF margin | 51.2% |
| Gross margin | 70.5% |
| ROIC | 0.1% |
| Total Debt to Equity | 23.5% |
Investment Thesis
Xperi is a technology licensing and IP company with a $304.5M market cap. The company’s quality rating of 6.1 is among the highest in this collection, and its intrinsic value is $56.3. Xperi’s revenue of $501.6M and a strong free cash flow margin 51.2% underscore its ability to monetize intellectual property. Despite a 1-year return of -26.4%, the company’s gross margin of 70.5% and positive free cash flow $257.0M suggest resilience.
Key Catalysts
- New licensing agreements and patent wins
- Expansion into emerging tech verticals
- Shareholder returns via buybacks or dividends
Risk Factors
- Dependence on IP litigation outcomes
- Modest revenue growth 0.9%
- Industry disruption risk
Genesco Inc. (GCO)
| Metric | Value |
|---|---|
| Market Cap | $301.5M |
| Quality Rating | 4.7 |
| Intrinsic Value | $163.1 |
| 1Y Return | 13.2% |
| Revenue | $2,362.2M |
| Free Cash Flow | $18.8M |
| Revenue Growth | 2.7% |
| FCF margin | 0.8% |
| Gross margin | 46.8% |
| ROIC | (2.1%) |
| Total Debt to Equity | 103.8% |
Investment Thesis
Genesco is a specialty retailer with a $301.5M market cap, operating in footwear and apparel. The company’s intrinsic value is $163.1, and it has delivered a positive 1-year return of 13.2%. Revenue growth 2.7% and a gross margin of 46.8% reflect steady operations. The quality rating of 4.7 and positive free cash flow $18.8M support a stable outlook, though the company faces a negative ROIC (2.1%) and moderate leverage.
Key Catalysts
- Expansion of e-commerce channels
- Brand portfolio optimization
- Seasonal sales growth
Risk Factors
- Negative ROIC and low FCF margin 0.8%
- Retail sector headwinds
- Inventory and supply chain risks
Kyverna Therapeutics, Inc. (KYTX)
| Metric | Value |
|---|---|
| Market Cap | $301.3M |
| Quality Rating | 5.7 |
| Intrinsic Value | $5.0 |
| 1Y Return | 45.8% |
| Revenue | $0.0 |
| Free Cash Flow | ($142.3M) |
| Revenue Growth | N/A |
| FCF margin | N/A |
| Gross margin | N/A |
| ROIC | 17,086.0% |
| Total Debt to Equity | 4.5% |
Investment Thesis
Kyverna Therapeutics is a clinical-stage biotech company with a $301.3M market cap. The company’s intrinsic value is $5.0, and it boasts a quality rating of 5.7. With no current revenue and negative free cash flow (142.3M), Kyverna is focused on advancing its pipeline in autoimmune and inflammatory diseases. The 1-year return of 45.8% indicates investor optimism around clinical progress.
Key Catalysts
- Positive clinical trial results
- Regulatory milestones
- Strategic collaborations
Risk Factors
- No revenue or gross margin
- High cash burn and negative FCF
- Clinical and regulatory risks
El Pollo Loco Holdings, Inc. (LOCO)
| Metric | Value |
|---|---|
| Market Cap | $298.6M |
| Quality Rating | 4.7 |
| Intrinsic Value | $27.1 |
| 1Y Return | -16.4% |
| Revenue | $480.8M |
| Free Cash Flow | $1,346.0K |
| Revenue Growth | 2.1% |
| FCF margin | 0.3% |
| Gross margin | 34.0% |
| ROIC | 8.2% |
| Total Debt to Equity | 21.6% |
Investment Thesis
El Pollo Loco is a fast-casual restaurant chain with a $298.6M market cap. The company’s intrinsic value is $27.1, and it maintains a quality rating of 4.7. Revenue of $480.8M and a gross margin of 34.0% support a stable business model. Despite a 1-year return of -16.4%, the company generates positive free cash flow $1.3M and demonstrates resilience in a competitive sector.
Key Catalysts
- Menu innovation and digital sales growth
- Franchise expansion
- Operational efficiency improvements
Risk Factors
- Modest revenue growth 2.1%
- Competitive pressures in fast-casual dining
- Margin compression risks
MicroVision, Inc. (MVIS)
| Metric | Value |
|---|---|
| Market Cap | $297.9M |
| Quality Rating | 5.0 |
| Intrinsic Value | $0.8 |
| 1Y Return | 15.8% |
| Revenue | $2,584.0K |
| Free Cash Flow | ($56.4M) |
| Revenue Growth | (71.3%) |
| FCF margin | (2,181.7%) |
| Gross margin | (130.8%) |
| ROIC | (170.3%) |
| Total Debt to Equity | 85.8% |
Investment Thesis
MicroVision is a technology company focused on lidar and sensor solutions, with a $297.9M market cap. The company’s intrinsic value is $0.8, and it has delivered a 1-year return of 15.8%. Despite negative revenue growth (71.3%) and a deeply negative free cash flow (56.4M), MicroVision’s technology positions it for potential upside if adoption accelerates.
Key Catalysts
- Commercial partnerships in automotive lidar
- New product launches
- Industry adoption of sensor technologies
Risk Factors
- High cash burn and negative margins
- Competitive technology landscape
- Execution risk in commercialization
Orion Engineered Carbons S.A. (OEC)
| Metric | Value |
|---|---|
| Market Cap | $297.6M |
| Quality Rating | 5.5 |
| Intrinsic Value | $29.5 |
| 1Y Return | -64.6% |
| Revenue | $1,841.7M |
| Free Cash Flow | $63.1M |
| Revenue Growth | (3.8%) |
| FCF margin | 3.4% |
| Gross margin | 21.4% |
| ROIC | 4.3% |
| Total Debt to Equity | 219.1% |
Investment Thesis
Orion Engineered Carbons is a specialty chemicals company with a $297.6M market cap. The company’s intrinsic value is $29.5, and it holds a quality rating of 5.5. Revenue of $1,841.7M and a gross margin of 21.4% reflect scale, though the 1-year return of -64.6% signals recent challenges. Positive free cash flow $63.1M and a 3.4% FCF margin support ongoing operations.
Key Catalysts
- Recovery in industrial demand
- Product innovation in specialty chemicals
- Cost optimization initiatives
Risk Factors
- High leverage (Total Debt to Equity: 219.1%)
- Negative revenue growth (3.8%)
- Cyclical industry exposure
Portfolio Diversification Insights
This watchlist spans technology, healthcare, consumer, and industrial sectors, providing a diversified exposure to both growth and value opportunities. The inclusion of early-stage biotech (KYTX), established consumer brands (JACK, LOCO), and technology innovators (VERI, MVIS, XPER) helps balance sector-specific risks. The mix of positive and negative 1-year returns reflects a contrarian approach, targeting both turnaround plays and momentum stocks.
Market Timing & Entry Strategies
Given current market volatility, staggered entry strategies—such as dollar-cost averaging or waiting for technical confirmation—can help manage risk. Investors may consider monitoring key catalysts (earnings, clinical trial results, product launches) and using ValueSense’s intrinsic value tools to identify optimal entry points[1][2]. Diversifying entry timing across sectors can further reduce portfolio risk.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- How VKTX (Viking Therapeutics) Makes Money in 2025: A Deep-Dive With Income Statement
- How NET (Cloudflare) Makes Money in 2025: A Deep-Dive With Income Statement
- How MASS (908 Devices) Makes Money in 2025: A Deep-Dive With Income Statement
- How CRVO (CervoMed) Makes Money in 2025: A Deep-Dive With Income Statement
- How GILD (Gilead Sciences) Makes Money in 2025: A Deep-Dive With Income Statement
FAQ Section
Q1: How were these stocks selected?
Stocks were screened using ValueSense’s proprietary intrinsic value models, quality ratings, and sector diversification filters, focusing on undervalued companies with strong or improving fundamentals[1][2].
Q2: What's the best stock from this list?
Each stock offers unique strengths; Xperi (XPER) stands out for its high quality rating and strong free cash flow, while Veritone (VERI) and Kyverna Therapeutics (KYTX) show significant growth potential based on recent performance and sector trends.
Q3: Should I buy all these stocks or diversify?
This collection is designed for diversification, spanning multiple sectors and risk profiles. Investors may consider allocating across several names to balance potential returns and risks.
Q4: What are the biggest risks with these picks?
Key risks include high leverage, negative cash flow, sector volatility, and execution challenges—especially for early-stage and turnaround companies. Each stock’s risk profile is detailed in its analysis section.
Q5: When is the best time to invest in these stocks?
Optimal timing depends on individual catalysts, technical setups, and market conditions. Monitoring ValueSense’s intrinsic value updates and company news can help identify attractive entry points[1][2].